

Table 4.25

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	439,817	99.5%	347,207	99.5%	50,670	99.3%	35,197	99.4%	1,595	99.3%	49,122	99.2%
Epidermoid carcinoma ^d (8051-8131)	199	0.0%	161	0.0%	24	0.0%	-	-	-	-	22	0.0%
Adenocarcinoma ^e	432,117	97.7%	341,551	97.9%	49,283	96.6%	34,677	97.9%	1,565	97.4%	48,132	97.2%
Adenocarcinoma, NOS (8140)	2,718	0.6%	2,115	0.6%	362	0.7%	178	0.5%	17	1.1%	300	0.6%
Infiltrating duct carcinoma (8500)	319,963	72.4%	249,944	71.6%	37,775	74.0%	27,256	76.9%	1,231	76.7%	36,663	74.0%
Lobular carcinoma, NOS (8520)	43,930	9.9%	37,210	10.7%	3,917	7.7%	2,246	6.3%	112	7.0%	3,952	8.0%
Inflammatory adenocarcinoma (8530)	865	0.2%	661	0.2%	140	0.3%	52	0.1%	-	-	159	0.3%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	43,090	9.7%	35,105	10.1%	4,318	8.5%	3,030	8.6%	131	8.2%	4,782	9.7%
Mucinous adenocarcinoma (8480,8482)	8,215	1.9%	6,146	1.8%	1,092	2.1%	871	2.5%	20	1.2%	887	1.8%
Mucin-producing adenocarcinoma (8481)	65	0.0%	49	0.0%	-	-	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	2,187	0.5%	1,941	0.6%	144	0.3%	69	0.2%	-	-	161	0.3%
Papillary adenocarcinoma (8050,8260,8503,8504)	3,326	0.8%	2,392	0.7%	522	1.0%	330	0.9%	18	1.1%	393	0.8%
Paget disease (8540-8543)	1,328	0.3%	1,065	0.3%	146	0.3%	90	0.3%	-	-	116	0.2%
Other adenocarcinomas ^f	6,430	1.5%	4,923	1.4%	858	1.7%	549	1.5%	20	1.2%	709	1.4%
Other specific carcinomas ^g	3,354	0.8%	2,469	0.7%	625	1.2%	223	0.6%	-	-	444	0.9%
Medullary adenocarcinoma (8510-8513)	689	0.2%	453	0.1%	178	0.3%	49	0.1%	-	-	150	0.3%
Other ^h	2,665	0.6%	2,016	0.6%	447	0.9%	174	0.5%	-	-	294	0.6%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	4,147	0.9%	3,026	0.9%	738	1.4%	284	0.8%	21	1.3%	524	1.1%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

ⁱ Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.25 - continued

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	445	0.1%	343	0.1%	63	0.1%	32	0.1%	-	-	55	0.1%
Hemangiosarcomas (9120-9126,9170)	252	0.1%	213	0.1%	24	0.0%	-	-	-	-	24	0.0%
Other sarcomas ^d	193	0.0%	130	0.0%	39	0.1%	19	0.1%	-	-	31	0.1%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	911	0.2%	636	0.2%	115	0.2%	129	0.4%	-	-	198	0.4%
Phyllodes tumor, malignant (9020)	784	0.2%	541	0.2%	91	0.2%	123	0.3%	-	-	175	0.4%
Other ^e	127	0.0%	95	0.0%	24	0.0%	-	-	-	-	23	0.0%
Unspecified (8000-8005)	1,005	0.2%	702	0.2%	172	0.3%	63	0.2%	-	-	153	0.3%
Total ^f	442,178	100.0%	348,888	100.0%	51,020	100.0%	35,421	100.0%	1,606	100.0%	49,528	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^e Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^f Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	112,659	99.9%	85,269	99.9%	13,833	99.9%	11,385	99.9%	346	99.7%	12,906	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^e	91,842	81.5%	68,384	80.1%	11,814	85.3%	9,993	87.7%	305	87.9%	10,610	82.1%
Cribriform carcinoma <i>in situ</i> (8201/2)	10,106	9.0%	7,450	8.7%	1,300	9.4%	1,171	10.3%	24	6.9%	1,139	8.8%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	8,130	7.2%	6,253	7.3%	890	6.4%	866	7.6%	28	8.1%	791	6.1%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	24,909	22.1%	18,910	22.2%	3,041	22.0%	2,411	21.2%	101	29.1%	2,864	22.2%
Comedocarcinoma <i>in situ</i> (8501/2)	8,251	7.3%	6,249	7.3%	943	6.8%	930	8.2%	31	8.9%	907	7.0%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,650	1.5%	1,072	1.3%	342	2.5%	196	1.7%	-	-	221	1.7%
Noninfiltrating intracystic carcinoma(8504/2)	362	0.3%	231	0.3%	59	0.4%	64	0.6%	-	-	37	0.3%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,502	1.3%	1,146	1.3%	211	1.5%	122	1.1%	-	-	170	1.3%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	36,670	32.5%	26,882	31.5%	5,007	36.2%	4,187	36.7%	112	32.3%	4,457	34.5%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	16,631	14.7%	13,576	15.9%	1,549	11.2%	1,042	9.1%	33	9.5%	1,840	14.2%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	16,617	14.7%	13,569	15.9%	1,543	11.1%	1,041	9.1%	33	9.5%	1,839	14.2%
Lobular CIS ^f with other CIS ^f (8524/2)	-	-	-	-	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	3,519	3.1%	2,822	3.3%	387	2.8%	266	2.3%	-	-	373	2.9%
Other adenocarcinomas ^g	661	0.6%	483	0.6%	82	0.6%	83	0.7%	-	-	83	0.6%
Other <i>in situ</i> histologies ^h	98	0.1%	66	0.1%	-	-	-	-	-	-	-	-
Total	112,757	100.0%	85,335	100.0%	13,847	100.0%	11,396	100.0%	347	100.0%	12,917	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^g CIS = Carcinoma *in situ*.

^h Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

ⁱ Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	21,852	97.6%	15,815	97.8%	3,286	96.2%	2,160	98.7%	157	98.1%	4,810	97.9%
Epidermoid carcinoma ^d (8050-8131)	14,411	64.4%	10,089	62.4%	2,497	73.1%	1,427	65.2%	113	70.6%	3,233	65.8%
Squamous cell carcinoma (8070)	10,489	46.9%	7,319	45.3%	1,849	54.1%	1,029	47.0%	88	55.0%	2,241	45.6%
Squamous cell, keratinizing (8071)	1,448	6.5%	1,009	6.2%	282	8.3%	122	5.6%	-	-	350	7.1%
Squamous cell, non-keratinizing (8072)	1,796	8.0%	1,300	8.0%	255	7.5%	193	8.8%	-	-	478	9.7%
Squamous cell, Microinvasive (8076)	295	1.3%	206	1.3%	45	1.3%	28	1.3%	-	-	65	1.3%
Other (8050-8069, 8073-8075,8077-8131)	383	1.7%	255	1.6%	66	1.9%	55	2.5%	-	-	99	2.0%
Adenocarcinoma ^e	6,464	28.9%	5,062	31.3%	611	17.9%	623	28.5%	39	24.4%	1,392	28.3%
Adenocarcinoma, NOS (8140)	3,262	14.6%	2,573	15.9%	295	8.6%	310	14.2%	16	10.0%	691	14.1%
Adenosquamous (8560,8570)	694	3.1%	505	3.1%	91	2.7%	84	3.8%	-	-	181	3.7%
Other adenocarcinomas ^f	2,508	11.2%	1,984	12.3%	225	6.6%	229	10.5%	16	10.0%	520	10.6%
Other specific carcinomas ^g	471	2.1%	315	1.9%	91	2.7%	59	2.7%	-	-	82	1.7%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	506	2.3%	349	2.2%	87	2.5%	51	2.3%	-	-	103	2.1%
Sarcoma ^h	113	0.5%	73	0.5%	33	1.0%	-	-	-	-	21	0.4%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	255	1.1%	170	1.1%	61	1.8%	18	0.8%	-	-	37	0.8%
Unspecified (8000-8005)	162	0.7%	112	0.7%	37	1.1%	-	-	-	-	43	0.9%
Total	22,382	100.0%	16,170	100.0%	3,417	100.0%	2,188	100.0%	160	100.0%	4,911	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.
^h Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	241,911	99.4%	188,153	99.5%	30,134	99.3%	19,065	99.3%	1,320	99.0%	28,315	99.3%
Epidermoid carcinoma ^d (8051-8131)	1,638	0.7%	1,378	0.7%	193	0.6%	29	0.2%	-	-	169	0.6%
Squamous cell carcinoma (8070-8078,8083-8084)	1,608	0.7%	1,358	0.7%	186	0.6%	28	0.1%	-	-	165	0.6%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	221,446	91.0%	173,696	91.8%	26,645	87.8%	17,463	91.0%	1,207	90.5%	25,545	89.6%
Adenocarcinoma, NOS (8140)	152,756	62.8%	119,478	63.2%	18,482	60.9%	12,497	65.1%	863	64.7%	17,859	62.7%
Adenocarcinoma in adenomatous polyp (8210)	21,938	9.0%	17,138	9.1%	2,474	8.2%	1,771	9.2%	135	10.1%	2,132	7.5%
Adenocarcinoma in villous adenoma (8261)	3,626	1.5%	2,932	1.5%	398	1.3%	249	1.3%	-	-	453	1.6%
Mucinous adenocarcinoma (8470-8473,8480,8482)	15,135	6.2%	12,237	6.5%	1,701	5.6%	1,024	5.3%	50	3.8%	1,947	6.8%
Mucin-producing adenocarcinoma (8481)	1,226	0.5%	962	0.5%	180	0.6%	71	0.4%	-	-	159	0.6%
Signet ring adenocarcinoma (8490)	2,703	1.1%	2,212	1.2%	282	0.9%	187	1.0%	-	-	316	1.1%
Other adenocarcinomas ^e	24,062	9.9%	18,737	9.9%	3,128	10.3%	1,664	8.7%	136	10.2%	2,679	9.4%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	16,991	7.0%	11,672	6.2%	3,038	10.0%	1,449	7.5%	86	6.5%	2,379	8.3%
Neuroendocrine carcinoid (8240-8245)	13,270	5.5%	8,843	4.7%	2,498	8.2%	1,202	6.3%	73	5.5%	1,967	6.9%
Other ^f	3,721	1.5%	2,829	1.5%	540	1.8%	247	1.3%	-	-	412	1.4%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,836	0.8%	1,407	0.7%	258	0.9%	124	0.6%	18	1.4%	222	0.8%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	160	0.1%	122	0.1%	22	0.1%	-	-	-	-	21	0.1%
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	434	0.2%	309	0.2%	69	0.2%	50	0.3%	-	-	48	0.2%
Unspecified (8000-8005)	798	0.3%	593	0.3%	114	0.4%	67	0.3%	-	-	119	0.4%
Total ^d	243,303	100.0%	189,177	100.0%	30,339	100.0%	19,195	100.0%	1,333	100.0%	28,503	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	27,552	99.2%	23,352	99.3%	2,597	99.0%	1,293	98.9%	135	99.3%	2,092	98.9%
Epidermoid carcinoma ^d (8051-8131)	8,653	31.2%	5,657	24.1%	1,986	75.7%	900	68.8%	54	39.7%	806	38.1%
Squamous cell carcinoma (8070-8078, 8083-8084)	8,632	31.1%	5,647	24.0%	1,978	75.4%	898	68.7%	54	39.7%	806	38.1%
Adenocarcinoma ^e	17,859	64.3%	16,794	71.4%	534	20.4%	344	26.3%	78	57.4%	1,200	56.7%
Other specific carcinomas ^f	424	1.5%	358	1.5%	34	1.3%	26	2.0%	-	-	32	1.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	616	2.2%	543	2.3%	43	1.6%	23	1.8%	-	-	54	2.6%
Other specific types ^g	99	0.4%	70	0.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	115	0.4%	96	0.4%	-	-	-	-	-	-	-	-
Total	27,766	100.0%	23,518	100.0%	2,624	100.0%	1,308	100.0%	136	100.0%	2,116	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma is defined as histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas is defined as histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^h Other specific types includes sarcomas and other soft tissue tumors.

ⁱ Other specific types is defined as histologies 8680-8713, 8720-8790, 8800-8921, 8930-8936, 8950-9030, 9040-9044, 9060-9110, 9120-9136, 9150-9252, 9260-9365, 9370-9373, 9380-9539, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	34,621	97.6%	24,847	97.5%	4,650	97.8%	4,527	97.8%	288	96.3%	5,883	96.7%
Hepatocellular carcinoma ^d (8170-8175)	24,131	68.0%	16,573	65.1%	3,608	75.9%	3,480	75.2%	233	77.9%	4,285	70.4%
Cholangiocarcinoma (8032-8033,8070-8071, 8140-8141,8160,8260, 8480-8481,8490,8560)	9,215	26.0%	7,362	28.9%	856	18.0%	893	19.3%	46	15.4%	1,405	23.1%
Other carcinoma ^e	1,260	3.6%	904	3.5%	186	3.9%	147	3.2%	-	-	191	3.1%
Other specific carcinoma ^f	900	2.5%	655	2.6%	117	2.5%	113	2.4%	-	-	132	2.2%
Unspecified, Carcinoma, NOS (8010,8020-8022,8031, 8046,8050)	360	1.0%	249	1.0%	69	1.5%	34	0.7%	-	-	59	1.0%
Hepatoblastoma (8970)	304	0.9%	219	0.9%	38	0.8%	35	0.8%	-	-	92	1.5%
Sarcoma ^g	297	0.8%	224	0.9%	29	0.6%	40	0.9%	-	-	45	0.7%
Hemangiosarcoma (9120)	141	0.4%	108	0.4%	-	-	21	0.5%	-	-	19	0.3%
Other sarcomas ^h	156	0.4%	116	0.5%	18	0.4%	19	0.4%	-	-	26	0.4%
Other specific types (8720,8980,8991,9061, 9064,9070-9071,9080, 9100)	55	0.2%	38	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8004)	195	0.5%	143	0.6%	25	0.5%	20	0.4%	-	-	49	0.8%
Total ^d	35,481	100.0%	25,477	100.0%	4,754	100.0%	4,629	100.0%	299	100.0%	6,086	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma arising from liver parenchyma are referred to as hepatocellular carcinoma.

^f Other carcinoma include histologies 8010, 8012-8013, 8020-8022, 8031, 8035, 8041-8042, 8046, 8050, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^g Other specific carcinoma include histologies 8012-8013, 8035, 8041-8042, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^h Sarcoma includes histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9120, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

ⁱ Other sarcomas include histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.28

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Both Sexes by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	47.8	319,082	99.8%	261,850	99.8%	34,890	99.8%	19,767	99.8%	1,089	99.8%	19,717	99.5%
Small cell (8002,8041-8045)	5.9	39,968	12.5%	34,951	13.3%	3,409	9.7%	1,335	6.7%	153	14.0%	2,029	10.2%
Non-small cell	40.5	269,735	84.3%	219,330	83.6%	30,289	86.6%	17,918	90.4%	886	81.2%	17,018	85.9%
Squamous and transitional cell ^d	10.9	72,205	22.6%	60,448	23.0%	8,247	23.6%	2,876	14.5%	326	29.9%	3,818	19.3%
Adenocarcinoma ^e	24.1	161,224	50.4%	128,729	49.0%	17,900	51.2%	13,318	67.2%	450	41.2%	10,664	53.8%
Large cell ^f	0.6	4,150	1.3%	3,361	1.3%	583	1.7%	183	0.9%	-	-	226	1.1%
Non-small cell carcinoma ^g	2.2	14,719	4.6%	11,919	4.5%	1,909	5.5%	765	3.9%	56	5.1%	929	4.7%
Other specified carcinomas ^h	2.6	17,437	5.5%	14,873	5.7%	1,650	4.7%	776	3.9%	46	4.2%	1,381	7.0%
Carcinoma, NOS ⁱ	1.4	9,379	2.9%	7,569	2.9%	1,192	3.4%	514	2.6%	50	4.6%	670	3.4%
Sarcoma ^j	0.1	496	0.2%	413	0.2%	47	0.1%	30	0.2%	-	-	68	0.3%
Other specified types ^k	0.0	269	0.1%	217	0.1%	34	0.1%	16	0.1%	-	-	28	0.1%
Total	47.9	319,847	100.0%	262,480	100.0%	34,971	100.0%	19,813	100.0%	1,091	100.0%	19,813	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Males by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	54.0	161,700	99.7%	130,845	99.7%	18,645	99.8%	10,935	99.8%	521	99.8%	10,085	99.5%
Small cell (8002,8041-8045)	6.3	19,443	12.0%	16,658	12.7%	1,693	9.1%	952	8.7%	77	14.8%	1,051	10.4%
Non-small cell	46.0	137,085	84.6%	110,067	83.9%	16,269	87.1%	9,672	88.2%	416	79.7%	8,664	85.5%
Squamous and transitional cell ^d	14.9	44,189	27.3%	36,643	27.9%	5,052	27.0%	2,118	19.3%	184	35.2%	2,363	23.3%
Adenocarcinoma ^e	24.9	74,619	46.0%	58,655	44.7%	8,949	47.9%	6,477	59.1%	172	33.0%	5,079	50.1%
Large cell ^f	0.8	2,357	1.5%	1,862	1.4%	353	1.9%	128	1.2%	-	-	137	1.4%
Non-small cell carcinoma ^g	2.8	8,320	5.1%	6,580	5.0%	1,151	6.2%	517	4.7%	34	6.5%	497	4.9%
Other specified carcinomas ^h	2.5	7,600	4.7%	6,327	4.8%	764	4.1%	432	3.9%	23	4.4%	588	5.8%
Carcinoma, NOS ⁱ	1.8	5,172	3.2%	4,120	3.1%	683	3.7%	311	2.8%	28	5.4%	370	3.7%
Sarcoma ^j	0.1	297	0.2%	252	0.2%	24	0.1%	17	0.2%	-	-	35	0.3%
Other specified types ^k	0.0	133	0.1%	104	0.1%	20	0.1%	-	-	-	-	-	-
Total	54.2	162,130	100.0%	131,201	100.0%	18,689	100.0%	10,960	100.0%	522	100.0%	10,131	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Females by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	43.1	157,382	99.8%	131,005	99.8%	16,245	99.8%	8,832	99.8%	568	99.8%	9,632	99.5%
Small cell (8002,8041-8045)	5.6	20,525	13.0%	18,293	13.9%	1,716	10.5%	383	4.3%	76	13.4%	978	10.1%
Non-small cell	36.4	132,650	84.1%	109,263	83.2%	14,020	86.1%	8,246	93.1%	470	82.6%	8,354	86.3%
Squamous and transitional cell ^d	7.7	28,016	17.8%	23,805	18.1%	3,195	19.6%	758	8.6%	142	25.0%	1,455	15.0%
Adenocarcinoma ^e	23.7	86,605	54.9%	70,074	53.4%	8,951	55.0%	6,841	77.3%	278	48.9%	5,585	57.7%
Large cell ^f	0.5	1,793	1.1%	1,499	1.1%	230	1.4%	55	0.6%	-	-	89	0.9%
Non-small cell carcinoma ^g	1.8	6,399	4.1%	5,339	4.1%	758	4.7%	248	2.8%	22	3.9%	432	4.5%
Other specified carcinomas ^h	2.7	9,837	6.2%	8,546	6.5%	886	5.4%	344	3.9%	23	4.0%	793	8.2%
Carcinoma, NOS ⁱ	1.1	4,207	2.7%	3,449	2.6%	509	3.1%	203	2.3%	22	3.9%	300	3.1%
Sarcoma ^j	0.1	199	0.1%	161	0.1%	23	0.1%	-	-	-	-	33	0.3%
Other specified types ^k	0.0	136	0.1%	113	0.1%	-	-	-	-	-	-	17	0.2%
Total	43.2	157,717	100.0%	131,279	100.0%	16,282	100.0%	8,853	100.0%	569	100.0%	9,682	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^f Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^g Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^h Non-small cell carcinoma includes histology 8046.

ⁱ Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

^j Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^k Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	65,066	85.7%	3,853	94.6%	23,258	97.8%	1,768	21.5%	3,023	95.6%
Squamous cell carcinoma (8070-8078,8083-8084)	63,615	83.7%	3,630	89.1%	22,916	96.4%	1,683	20.4%	2,981	94.3%
Adenocarcinoma ^c	7,410	9.8%	162	4.0%	272	1.1%	5,166	62.7%	114	3.6%
Other specific carcinomas ^d	700	0.9%	-	-	60	0.3%	431	5.2%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,912	2.5%	-	-	102	0.4%	543	6.6%	-	-
Sarcoma and soft tissue ^e	222	0.3%	-	-	34	0.1%	46	0.6%	-	-
Other specific types ^f	395	0.5%	29	0.7%	-	-	204	2.5%	-	-
Unspecified (8000-8005)	256	0.3%	-	-	47	0.2%	75	0.9%	-	-
Total	75,961	100.0%	4,074	100.0%	23,784	100.0%	8,233	100.0%	3,161	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	8,346	82.7%	2,652	68.1%	17,005	98.3%	3,674	97.1%	1,487	90.5%
Squamous cell carcinoma (8070-8078,8083-8084)	7,922	78.5%	2,511	64.5%	16,854	97.4%	3,642	96.2%	1,476	89.8%
Adenocarcinoma ^c	1,420	14.1%	127	3.3%	98	0.6%	25	0.7%	26	1.6%
Other specific carcinomas ^d	50	0.5%	45	1.2%	54	0.3%	31	0.8%	16	1.0%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	79	0.8%	1,002	25.7%	82	0.5%	27	0.7%	60	3.6%
Sarcoma and soft tissue ^e	47	0.5%	42	1.1%	20	0.1%	16	0.4%	-	-
Other specific types ^f	118	1.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	26	0.3%	-	-	31	0.2%	-	-	41	2.5%
Total	10,086	100.0%	3,896	100.0%	17,298	100.0%	3,785	100.0%	1,644	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	33,351	91.1%	26,960	91.5%	3,062	87.7%	2,868	91.9%	129	84.3%	4,351	87.8%
Epidermoid carcinoma ^d (8051-8131)	195	0.5%	149	0.5%	21	0.6%	23	0.7%	-	-	32	0.6%
Adenocarcinoma ^e	30,785	84.1%	25,075	85.1%	2,638	75.6%	2,658	85.2%	120	78.4%	3,962	79.9%
Adenocarcinoma, NOS (8140)	3,578	9.8%	2,882	9.8%	443	12.7%	224	7.2%	-	-	463	9.3%
Papillary adenocarcinoma, NOS (8050,8260)	229	0.6%	173	0.6%	41	1.2%	-	-	-	-	30	0.6%
Clear cell adenocarcinoma (8310,9110)	2,160	5.9%	1,618	5.5%	113	3.2%	399	12.8%	-	-	269	5.4%
Endometrioid carcinoma (8380-8383,8570)	3,511	9.6%	2,854	9.7%	208	6.0%	391	12.5%	-	-	512	10.3%
Cystadenocarcinoma, NOS (8440,8450)	59	0.2%	52	0.2%	-	-	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	13,360	36.5%	11,015	37.4%	1,160	33.2%	1,000	32.0%	60	39.2%	1,549	31.2%
Papillary serous cystadenocarcinoma (8460-8462)	4,107	11.2%	3,429	11.6%	376	10.8%	252	8.1%	18	11.8%	581	11.7%
Mucinous cystadenocarcinoma (8470-8473)	356	1.0%	271	0.9%	34	1.0%	41	1.3%	-	-	56	1.1%
Mucinous adenocarcinoma (8480,8482)	1,611	4.4%	1,275	4.3%	138	4.0%	171	5.5%	-	-	220	4.4%
Mucin-producing adenocarcinoma(8481)	24	0.1%	20	0.1%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,790	4.9%	1,486	5.0%	117	3.4%	163	5.2%	-	-	266	5.4%
Other specific carcinomas ^g	959	2.6%	623	2.1%	238	6.8%	72	2.3%	-	-	183	3.7%
Stromal cell tumor (8620-8631,8650)	729	2.0%	459	1.6%	198	5.7%	49	1.6%	-	-	145	2.9%
Other ^h	230	0.6%	164	0.6%	40	1.1%	23	0.7%	-	-	38	0.8%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,412	3.9%	1,113	3.8%	165	4.7%	115	3.7%	-	-	174	3.5%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	109	0.3%	86	0.3%	19	0.5%	-	-	-	-	19	0.4%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	2,785	7.6%	2,141	7.3%	343	9.8%	222	7.1%	17	11.1%	536	10.8%
Mullerian mixed tumor (8950-8951,8980)	1,335	3.6%	1,092	3.7%	146	4.2%	72	2.3%	-	-	146	2.9%
Teratoma, malignant (9080-9085,9102)	539	1.5%	345	1.2%	99	2.8%	66	2.1%	-	-	168	3.4%
Other	911	2.5%	704	2.4%	98	2.8%	84	2.7%	-	-	222	4.5%
Unspecified (8000-8005)	381	1.0%	269	0.9%	66	1.9%	29	0.9%	-	-	51	1.0%
Total ^d	36,626	100.0%	29,456	100.0%	3,490	100.0%	3,121	100.0%	153	100.0%	4,957	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	72,717	98.5%	58,010	98.5%	9,047	98.4%	4,974	98.3%	251	97.7%	7,796	98.1%
Epidermoid carcinoma ^d (8051-8131)	198	0.3%	149	0.3%	28	0.3%	16	0.3%	-	-	26	0.3%
Adenocarcinoma ^e	62,748	85.0%	50,250	85.3%	7,767	84.5%	4,188	82.8%	211	82.1%	6,651	83.6%
Adenocarcinoma, NOS (8140)	49,487	67.0%	39,612	67.3%	6,284	68.3%	3,178	62.8%	167	65.0%	5,135	64.6%
Papillary adenocarcinoma, NOS (8260)	40	0.1%	31	0.1%	-	-	-	-	-	-	-	-
Mucinous adenocarcinoma (8480,8482)	1,550	2.1%	1,274	2.2%	141	1.5%	116	2.3%	-	-	177	2.2%
Mucin-producing adenocarcinoma (8481)	354	0.5%	278	0.5%	52	0.6%	22	0.4%	-	-	34	0.4%
Infiltrating duct carcinoma (8500-8503,8507,8514)	9,099	12.3%	7,283	12.4%	1,039	11.3%	692	13.7%	31	12.1%	971	12.2%
Other adenocarcinoma ^f	2,218	3.0%	1,772	3.0%	247	2.7%	175	3.5%	-	-	328	4.1%
Other specific carcinomas ^g	7,494	10.1%	5,895	10.0%	894	9.7%	589	11.6%	26	10.1%	846	10.6%
Islet cell carcinoma (8150-8155)	328	0.4%	267	0.5%	40	0.4%	17	0.3%	-	-	21	0.3%
Other carcinomas ^h	7,166	9.7%	5,628	9.6%	854	9.3%	572	11.3%	25	9.7%	825	10.4%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	2,278	3.1%	1,717	2.9%	358	3.9%	181	3.6%	-	-	274	3.4%
Sarcoma and other soft tissue tumors ⁱ	62	0.1%	50	0.1%	-	-	-	-	-	-	-	-
Other specific types ^j	75	0.1%	57	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	984	1.3%	767	1.3%	130	1.4%	74	1.5%	-	-	132	1.7%
Total	73,839	100.0%	58,885	100.0%	9,194	100.0%	5,061	100.0%	257	100.0%	7,951	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

^j Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	42,491	90.9%	30,259	92.0%	5,698	84.4%	5,719	92.1%	269	96.8%	8,087	93.9%
Epidermoid carcinoma ^d (8051-8131)	413	0.9%	288	0.9%	76	1.1%	45	0.7%	-	-	48	0.6%
Squamous cell carcinoma (8070-8078,8083-8084)	391	0.8%	274	0.8%	73	1.1%	40	0.6%	-	-	41	0.5%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	37,210	79.6%	26,353	80.1%	4,923	72.9%	5,308	85.5%	240	86.3%	7,006	81.3%
Adenocarcinoma, NOS (8140)	21,488	46.0%	15,899	48.3%	2,753	40.8%	2,502	40.3%	125	45.0%	3,396	39.4%
Adenocarcinoma, intestinal type (8144)	3,796	8.1%	2,172	6.6%	652	9.7%	902	14.5%	28	10.1%	737	8.6%
Carcinoma, diffuse type (8145)	1,757	3.8%	1,081	3.3%	215	3.2%	427	6.9%	-	-	481	5.6%
Linitus plastica (8142)	168	0.4%	126	0.4%	16	0.2%	22	0.4%	-	-	38	0.4%
Mucinous adenocarcinoma (8470-8473,8480,8482)	526	1.1%	371	1.1%	85	1.3%	59	1.0%	-	-	99	1.1%
Mucin-producing adenocarcinoma (8481)	118	0.3%	81	0.2%	21	0.3%	16	0.3%	-	-	25	0.3%
Signet ring adenocarcinoma (8490)	7,368	15.8%	5,268	16.0%	865	12.8%	1,086	17.5%	58	20.9%	1,842	21.4%
Other adenocarcinomas ^e	1,989	4.3%	1,355	4.1%	316	4.7%	294	4.7%	-	-	388	4.5%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	4,009	8.6%	3,033	9.2%	550	8.1%	253	4.1%	25	9.0%	880	10.2%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	859	1.8%	585	1.8%	149	2.2%	113	1.8%	-	-	153	1.8%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22 - continued

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	106	0.2%	88	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	3,943	8.4%	2,404	7.3%	1,021	15.1%	450	7.2%	-	-	469	5.4%
Unspecified (8000-8005)	210	0.4%	148	0.4%	27	0.4%	30	0.5%	-	-	48	0.6%
Total ^d	46,750	100.0%	32,899	100.0%	6,754	100.0%	6,208	100.0%	278	100.0%	8,613	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	95,669	99.7%	75,724	99.7%	7,096	99.6%	10,083	99.8%	391	100.0%	15,610	99.7%
Epidermoid carcinoma ^d (8051-8131)	107	0.1%	85	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	92,789	96.7%	73,437	96.7%	6,793	95.3%	9,850	97.5%	379	96.9%	15,177	96.9%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	86,543	90.2%	68,561	90.3%	6,061	85.0%	9,359	92.6%	356	91.0%	14,329	91.5%
Follicular carcinoma (8330-8332,8335)	4,126	4.3%	3,135	4.1%	540	7.6%	344	3.4%	-	-	582	3.7%
Oxyphilic (8290)	1,669	1.7%	1,376	1.8%	150	2.1%	109	1.1%	-	-	196	1.3%
Other specific carcinomas ^f	1,614	1.7%	1,321	1.7%	164	2.3%	95	0.9%	-	-	251	1.6%
Medullary carcinoma (8510)	1,562	1.6%	1,281	1.7%	161	2.3%	88	0.9%	-	-	244	1.6%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	1,159	1.2%	881	1.2%	130	1.8%	127	1.3%	-	-	167	1.1%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	782	0.8%	614	0.8%	74	1.0%	82	0.8%	-	-	120	0.8%
Sarcoma and other soft tissue tumors ^g	22	0.0%	16	0.0%	-	-	-	-	-	-	-	-
Other specific types ^h	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	240	0.3%	171	0.2%	27	0.4%	18	0.2%	-	-	41	0.3%
Total	95,939	100.0%	75,918	100.0%	7,127	100.0%	10,102	100.0%	391	100.0%	15,658	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

^g Sarcoma and other soft tissue tumors include histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^h Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.